NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Totus Medicines

Totus Medicines

Private
Emeryville, CaliforniaHealthcare & Life Scienceshttps://www.totusmedicines.com/

Last Round

Series B

Dec 15, 2023

Total Funding Raised

$109M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Totus Medicines is a biotechnology company that develops precision oral medicines for previously untreatable diseases using its proprietary AI-powered OmniDEL drug discovery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

drug discoverysmall molecule therapeuticscovalent chemistryAI drug discoveryDNA-encoded libraryundruggable targetsin silico drug discoveryhigh-throughput screeningoncology therapeuticsimmunology researchbiotech platformsmall molecule inhibitorscomputational biologypharma partnershippreclinical development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Totus Medicines Comparables

Compare Totus Medicines with similar companies based on industry and business-model similarity.

Totus Medicines comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Frontier Medicines
89%
Matchpoint Therapeutics
86%
Nexo Therapeutics
85%

Totus Medicines Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 15, 2023
Series ADec 9, 2021

Key People

Founding team and executive leadership

Nassim Usman

President Chief Executive Officer

Executive Team

Simon Harnest

Chief Financial Officer

Executive Team

Totus Medicines Investors

Notable investors and investment history

Totus Medicines investors
InvestorRounds
DCVC BioSeries A, Series B
Camford CapitalSeries A, Series B
Northpond VenturesSeries B, Series A
Social Impact CapitalSeries A, Pre Seed, Seed
University of MinnesotaSeries B
Northpond VenturesSeries B, Series A
Camford CapitalSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Presenting data on covalent IRF5 inhibitor at AAI IMMUNOLOGY2026.

  • Apr 16, 2026

    Presenting data at the AAI IMMUNOLOGY2026 event.

Totus Medicines Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Totus Medicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Totus Medicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersEmeryville, California
Employee Range36
Year Founded2019
Last FundingDec 15, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.